MX2019004626A - Compuesto de piridona como inhibidor de c-met. - Google Patents

Compuesto de piridona como inhibidor de c-met.

Info

Publication number
MX2019004626A
MX2019004626A MX2019004626A MX2019004626A MX2019004626A MX 2019004626 A MX2019004626 A MX 2019004626A MX 2019004626 A MX2019004626 A MX 2019004626A MX 2019004626 A MX2019004626 A MX 2019004626A MX 2019004626 A MX2019004626 A MX 2019004626A
Authority
MX
Mexico
Prior art keywords
met inhibitor
pyridone compound
compound
pyridone
disclosed
Prior art date
Application number
MX2019004626A
Other languages
English (en)
Inventor
Wang Kun
Z Ding Charles
Hu Lihong
Li Gang
Hu Guoping
Chen Shuhui
Li Jian
Xu Xiongbin
Chi Zhigang
Original Assignee
Fujian Cosunter Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62024383&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019004626(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fujian Cosunter Pharmaceutical Co Ltd filed Critical Fujian Cosunter Pharmaceutical Co Ltd
Publication of MX2019004626A publication Critical patent/MX2019004626A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

En la presente invención se describe un tipo de compuestos de piridona como inhibidores de c-met, y se describe específicamente un compuesto como se muestra en la fórmula (I) o una sal farmacéuticamente aceptable del mismo (ver fórmula I).
MX2019004626A 2016-10-27 2017-10-27 Compuesto de piridona como inhibidor de c-met. MX2019004626A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201610954377 2016-10-27
PCT/CN2017/107964 WO2018077227A1 (zh) 2016-10-27 2017-10-27 作为c-MET抑制剂的吡啶酮类化合物

Publications (1)

Publication Number Publication Date
MX2019004626A true MX2019004626A (es) 2019-11-08

Family

ID=62024383

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019004626A MX2019004626A (es) 2016-10-27 2017-10-27 Compuesto de piridona como inhibidor de c-met.

Country Status (28)

Country Link
US (1) US10501443B2 (es)
EP (1) EP3533787B1 (es)
JP (1) JP6719679B2 (es)
KR (1) KR102070748B1 (es)
CN (1) CN109311812B (es)
AU (1) AU2017348810B2 (es)
BR (1) BR112019008415B1 (es)
CA (1) CA3041164C (es)
CO (1) CO2019005165A2 (es)
DK (1) DK3533787T3 (es)
EA (1) EA038108B1 (es)
ES (1) ES2835301T3 (es)
HR (1) HRP20201985T1 (es)
HU (1) HUE051734T2 (es)
IL (1) IL266126B (es)
LT (1) LT3533787T (es)
MX (1) MX2019004626A (es)
MY (1) MY189557A (es)
PE (1) PE20190912A1 (es)
PH (1) PH12019500875A1 (es)
PL (1) PL3533787T3 (es)
PT (1) PT3533787T (es)
RS (1) RS61126B1 (es)
SG (1) SG11201903801YA (es)
SI (1) SI3533787T1 (es)
UA (1) UA122737C2 (es)
WO (1) WO2018077227A1 (es)
ZA (1) ZA201903074B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA039713B1 (ru) * 2018-04-26 2022-03-03 Фуцзянь Косантер Фармасьютикал Ко., Лтд. Кристаллическая форма ингибитора c-met, его солевая форма и способ их получения
EP3919492A4 (en) * 2019-02-01 2022-11-09 Medshine Discovery Inc. TRICYCLIC COMPOUND CONTAINING PYRIMIDINYL GROUP AS C-MET INHIBITOR
WO2022063869A2 (en) 2020-09-24 2022-03-31 Merck Patent Gmbh Compounds for the treatment of viral infections
CA3222061A1 (en) 2021-06-04 2022-12-08 Merck Patent Gmbh Compounds for the treatment of glioblastoma

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001275857A1 (en) * 2000-06-29 2002-01-14 Bristol-Myers Squibb Pharma Company Thrombin or factor xa inhibitors
EP1741703A4 (en) 2004-03-05 2009-11-25 Banyu Pharma Co Ltd PYRIDONE DERIVATIVE
AU2008219166B2 (en) * 2007-02-16 2013-05-16 Amgen Inc. Nitrogen-containing heterocyclyl ketones and their use as c-Met inhibitors
DE102007032507A1 (de) * 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102008062826A1 (de) * 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
WO2013057101A1 (de) 2011-10-17 2013-04-25 Bayer Intellectual Property Gmbh Substituierte oxadiazolylpyridinone und - pyridazinone als hif - hemmer
RU2014141934A (ru) * 2012-03-19 2016-05-20 Мерк Патент Гмбх Комбинация производного 6-оксо-1,6-дигидро-пиридазина, которая обладает противораковым действием с другими противоопухолевыми соединениями
US20150297594A1 (en) * 2012-10-11 2015-10-22 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a MEK inhibitor
US10231972B2 (en) 2014-12-11 2019-03-19 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with a quinazoline derivative

Also Published As

Publication number Publication date
HUE051734T2 (hu) 2021-03-29
CO2019005165A2 (es) 2019-05-31
JP2019535806A (ja) 2019-12-12
EP3533787A1 (en) 2019-09-04
CN109311812A (zh) 2019-02-05
DK3533787T3 (da) 2020-11-30
AU2017348810A1 (en) 2019-05-23
ZA201903074B (en) 2020-01-29
IL266126A (en) 2019-06-30
AU2017348810B2 (en) 2020-05-07
RS61126B1 (sr) 2020-12-31
HRP20201985T1 (hr) 2021-02-05
NZ753020A (en) 2021-08-27
US20190248763A1 (en) 2019-08-15
UA122737C2 (uk) 2020-12-28
CA3041164C (en) 2019-12-17
EA038108B1 (ru) 2021-07-07
EA201990952A1 (ru) 2019-11-29
LT3533787T (lt) 2020-11-25
PE20190912A1 (es) 2019-06-26
BR112019008415B1 (pt) 2020-09-29
PL3533787T3 (pl) 2021-03-08
SG11201903801YA (en) 2019-05-30
JP6719679B2 (ja) 2020-07-08
WO2018077227A1 (zh) 2018-05-03
EP3533787A4 (en) 2019-11-13
KR20190058678A (ko) 2019-05-29
CN109311812B (zh) 2020-03-17
ES2835301T3 (es) 2021-06-22
SI3533787T1 (sl) 2021-01-29
KR102070748B1 (ko) 2020-01-29
MY189557A (en) 2022-02-16
PH12019500875A1 (en) 2019-06-17
BR112019008415A2 (pt) 2019-07-09
CA3041164A1 (en) 2018-05-03
IL266126B (en) 2020-07-30
US10501443B2 (en) 2019-12-10
EP3533787B1 (en) 2020-09-30
PT3533787T (pt) 2020-11-20

Similar Documents

Publication Publication Date Title
PH12015502031A1 (en) Tetrahydropyrrolothiazine compounds
PH12017501523A1 (en) Selective bace1 inhibitors
GEP20207111B (en) Heteroaryl compounds for kinase inhibition
PH12016500467B1 (en) Aminoheteroarlyl benzamides as kinase inhibitors
MX2017006266A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas al receptor de interleucina 1(irak) y sus usos.
NZ729005A (en) Aminopyrimidinyl compounds as jak inhibitors
PH12016501388A1 (en) Heteroaryls and uses thereof
MA39749A (fr) Dérivés de pipéridine-dione
PH12017502051A1 (en) TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF
PH12019500875A1 (en) Pyridone compound as c-met inhibitor
MX2022014864A (es) Compuestos de bisamida que activan el sarcomero y sus usos.
MA40059A (fr) Inhibiteurs de la phosphatidylinositol 3-kinase
PH12019501022A1 (en) Pyrazolopyrimidine compounds and methods of use thereof
MX2015017156A (es) Inhibidores de bace.
MX368496B (es) Análogos de compuestos de 4h-pirazolo[1,5-a]bencimidazol como inhibidores parp.
MY193239A (en) Novel b-lactamase inhibitors
MX2018014813A (es) Composiciones antibacterianas.
TW201612165A (en) Preparation method for aromatic heterocyclic compound used as selective jak3 and/or jak1 kinase inhibitor and application of aromatic heterocyclic compound
PH12019500370A1 (en) Triazolopyrazinone derivative useful as a human pde1 inhibitor
TW201613898A (en) Benzofuran analogue as NS4B inhibitor

Legal Events

Date Code Title Description
FG Grant or registration